Hoxton Planning & Management’s Stryker SYK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$621K Buy
1,973
+30
+2% +$9.45K 0.16% 108
2026
Q1
$638K Sell
1,943
-11
-0.6% -$3.95K 0.19% 91
2025
Q4
$687K Sell
1,954
-5
-0.3% -$1.82K 0.21% 83
2025
Q3
$724K Sell
1,959
-6
-0.3% -$2.32K 0.23% 80
2025
Q2
$777K Sell
1,965
-6
-0.3% -$2.25K 0.27% 73
2025
Q1
$734K Buy
1,971
+20
+1% +$7.61K 0.28% 72
2024
Q4
$702K Sell
1,951
-1
-0.1% -$371 0.27% 74
2024
Q3
$705K Buy
1,952
+25
+1% +$8.63K 0.27% 68
2024
Q2
$656K Sell
1,927
-22
-1% -$7.45K 0.31% 63
2024
Q1
$697K Buy
1,949
+22
+1% +$7.4K 0.33% 58
2023
Q4
$577K Sell
1,927
-33
-2% -$9.26K 0.31% 61
2023
Q3
$536K Sell
1,960
-6
-0.3% -$1.72K 0.35% 61
2023
Q2
$600K Sell
1,966
-105
-5% -$30.3K 0.37% 51
2023
Q1
$591K Buy
2,071
+18
+0.9% +$4.78K 0.33% 62
2022
Q4
$502K Buy
+2,053
New +$466K 0.27% 78

Other funds holding SYK

Hoxton Planning & Management's SYK Position: Q2 2026 in Review

Hoxton Planning & Management increased its Stryker (SYK) stake by 1.5% in Q2 2026, buying an estimated $9.45K and bringing the position to 1,973 shares worth $621K. The position accounts for 0.16% of the portfolio, ranked #108.

Hoxton Planning & Management first reported a position in SYK in Q4 2022 and has held it in 15 quarters since. The position peaked at $777K in Q2 2025. 522 funds tracked by Wall St. Rank hold SYK as of Q2 2026.

  • Hoxton Planning & Management held 1,973 shares of Stryker worth $621K as of Q2 2026.
  • Hoxton Planning & Management bought 30 Stryker shares in Q2 2026, an estimated $9.45K.
  • Stryker made up 0.16% of Hoxton Planning & Management's portfolio in Q2 2026, its #108 holding.
  • Hoxton Planning & Management first reported a position in Stryker in Q4 2022 and has held it in 15 quarters since.
  • Hoxton Planning & Management's Stryker position peaked at $777K in Q2 2025.
  • 522 funds tracked by Wall St. Rank held Stryker as of Q2 2026.

Based on Hoxton Planning & Management's 13F filing for Q2 2026, filed 16 Jul 2026.